2020 Nelson's Pediatric Antimicrobial Therapy

By:

John Scott Bradley

Contributor(s):

Material type: Text

TextPublication details: New York American Academy of Pediatrics 2020 Edition: 26th EditionDescription: 320 pagesISBN:

9781610023528
1610023528

Subject(s):

-- Anti-infective agents

Summary: The 26th edition provides practical, evidence-based recommendations from the experts in antimicrobial therapy for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices. Drug descriptions cover pediatric-appropriate antimicrobial agents available today and include complete information about dosing regimens. New in the 26th edition: First pediatric approval of beta-lactam/beta-lactamase inhibitor for CRE (carbapenem-resistant enteric bacilli), ceftazidime-avibactam Replacement antibiotics for cefotaxime (lack of availability in the US), including ceftriaxone and cefepime (for neonates) Situations in which ceftaroline is preferred over vancomycin by the Editors for MRSA infections Updates on management of influenza, including baloxavir (now approved for children >12 years) New approaches to treatment of mucomycosis New recommendations for malaria More than 150 new references!

Item type: E-BOOKS

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Collection	Status	Barcode
E-BOOKS	MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO	NFIC	2	EBS8275

Total holds: 0

The 26th edition provides practical, evidence-based recommendations from the experts in antimicrobial therapy for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices.
Drug descriptions cover pediatric-appropriate antimicrobial agents available today and include complete information about dosing regimens.

New in the 26th edition:

First pediatric approval of beta-lactam/beta-lactamase inhibitor for CRE (carbapenem-resistant enteric bacilli), ceftazidime-avibactam
Replacement antibiotics for cefotaxime (lack of availability in the US), including ceftriaxone and cefepime (for neonates)
Situations in which ceftaroline is preferred over vancomycin by the Editors for MRSA infections
Updates on management of influenza, including baloxavir (now approved for children >12 years)
New approaches to treatment of mucomycosis
New recommendations for malaria
More than 150 new references!

There are no comments on this title.

to post a comment.